{
    "clinical_study": {
        "@rank": "149706", 
        "acronym": "SUSTAIN\u2122 2", 
        "arm_group": [
            {
                "arm_group_label": "Semaglutide 0.5 mg + sitagliptin placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Semaglutide 1.0 mg + sitagliptin placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg + semaglutide placebo 1.0 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg + semaglutide placebo 0.5 mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, Asia, Europe and South and North America. The aim of the\n      trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin\n      once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2\n      diabetes."
        }, 
        "brief_title": "Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japan: Age minimum 20 years\n\n          -  Subjects diagnosed with type 2 diabetes and on stable treatment in a period of 90\n             days prior to screening with either metformin above or equal to 1500 mg (or maximum\n             tolerated dose), pioglitazone above or equal to 30 mg (or maximum tolerated dose),\n             rosiglitazone above or equal to 4 mg (or maximum tolerated dose) or a combination of\n             either metformin/pioglitazone or metformin/rosiglitazone (doses as for individual\n             therapies). Stable is defined as unchanged medication and unchanged dose\n\n          -  HbA1c 7.0 - 10.5 % (53 - 91 mmol/mol) (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Females of childbearing potential who are pregnant, breast-feeding or intend to\n             become pregnant or are not using an adequate contraceptive method throughout the\n             trial including the 5 weeks follow-up period (adequate contraceptive measures as\n             required by local law or practice)\n\n          -  Any chronic disorder or severe disease which, in the opinion of the investigator,\n             might jeopardise subject's safety or compliance with the protocol\n\n          -  Treatment with glucose lowering agent(s) other than stated in the inclusion criteria\n             in a period of 90 days before screening. An exception is short-term treatment (below\n             or equal to 7 days in total) with insulin in connection with inter-current illness\n\n          -  History of chronic or idiopathic acute pancreatitis\n\n          -  Screening calcitonin value above or equal to 50 ng/L (pg/mL)\n\n          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine\n             neoplasia syndrome type 2 (MEN 2)\n\n          -  Impaired renal function defined as estimated glomerular filtration rate (eGFR) below\n             60 ml/min/1.73 m2 per modification of diet in renal disease (MDRD) formula (4\n             variable version)\n\n          -  Acute coronary or cerebrovascular event within 90 days before randomisation\n\n          -  Heart failure, New York Heart Association (NYHA) class IV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930188", 
            "org_study_id": "NN9535-3626", 
            "secondary_id": [
                "2012-004827-19", 
                "U1111-1135-8730", 
                "132366"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Semaglutide 0.5 mg + sitagliptin placebo", 
                    "Semaglutide 1.0 mg + sitagliptin placebo"
                ], 
                "description": "For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin 100 mg + semaglutide placebo 1.0 mg", 
                    "Sitagliptin 100 mg + semaglutide placebo 0.5 mg"
                ], 
                "description": "Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.", 
                "intervention_name": "sitagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Semaglutide 0.5 mg + sitagliptin placebo", 
                    "Semaglutide 1.0 mg + sitagliptin placebo"
                ], 
                "description": "Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sitagliptin 100 mg + semaglutide placebo 1.0 mg", 
                    "Sitagliptin 100 mg + semaglutide placebo 0.5 mg"
                ], 
                "description": "For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sitagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Caba", 
                        "country": "Argentina", 
                        "zip": "C1179AAB"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ruse", 
                        "country": "Bulgaria", 
                        "zip": "7000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4- Chodov", 
                        "country": "Czech Republic", 
                        "zip": "149 00"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary", 
                        "zip": "H-6701"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "600116"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mito-shi, Ibaraki", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n", 
                        "zip": "64620"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kongsvinger", 
                        "country": "Norway", 
                        "zip": "2212"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal", 
                        "zip": "1250-230"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brasov", 
                        "country": "Romania", 
                        "zip": "500365"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "119881"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "state": "KwaZulu-Natal", 
                        "zip": "4001"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "zip": "07010"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "222 22"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34752"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnitsa", 
                        "country": "Ukraine", 
                        "zip": "21010"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Argentina", 
                "Bulgaria", 
                "Czech Republic", 
                "Hong Kong", 
                "Hungary", 
                "India", 
                "Japan", 
                "Mexico", 
                "Norway", 
                "Portugal", 
                "Romania", 
                "Russian Federation", 
                "South Africa", 
                "Spain", 
                "Sweden", 
                "Thailand", 
                "Turkey", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN\u2122 2 - vs. DPP-4 Inhibitor)", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Bulgaria: Ministry of Health", 
                "Hong Kong: Department of Health", 
                "India: Ministry of Health", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Norway: Norwegian Medicines Agency", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Russia: Ministry of Health of the Russian Federation", 
                "South Africa: Medicines Control Council", 
                "Spain: Spanish Agency of Medicines", 
                "Sweden: Medical Products Agency", 
                "Thailand: Ministry of Public Health", 
                "Turkey: Ministry of Health", 
                "Ukraine: Ministry of Health", 
                "United States: Food and Drug Administration", 
                "Czech Republic: State Institute for Drug Control"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c (glycosylated haemoglobin) from baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 56"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in body weight from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 56"
            }, 
            {
                "measure": "Change in fasting plasma glucose (FPG) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 56"
            }, 
            {
                "measure": "Change in systolic and diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 56"
            }, 
            {
                "measure": "Change in patient reported outcome (PRO) questionnaire Diabetes Treatment Satisfaction Questionnaire status (DTSQs) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 56"
            }, 
            {
                "measure": "Subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "After 56 weeks treatment"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}